| Author | Lima, Mauricio Teixeira | |
| Author | Kroon, Erna Geessien | |
| Author | Campos, Marco Antônio | |
| Access date | 2025-04-14T17:13:58Z | |
| Available date | 2025-04-14T17:13:58Z | |
| Document date | 2025 | |
| Citation | LIMA, Mauricio Teixeira; KROON, Erna Geessien; CAMPOS, Marco Antônio. Mpox and the impact on people with HIV. Current Opinion in HIV and AIDS, v. 20, n. 2, p. 310-317, 2025. | en_US |
| ISSN | 1746-630X | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/69628 | |
| Language | eng | en_US |
| Publisher | Lippincott Williams & Wilkins | en_US |
| Rights | restricted access | en_US |
| Title | Mpox and the impact on people with HIV. | en_US |
| Type | Article | en_US |
| DOI | 10.1097/COH.0000000000000922 | |
| Abstract | Purpose of review: This review explores the intersection of Mpox and HIV, highlighting clinical manifestations, immune evasion mechanisms, epidemiological challenges, and prevention strategies. People with HIV (PWH), particularly those with low CD4+ cell count, face severe Mpox outcomes. Prevention relies on education, vaccination, and early detection. Integrating Mpox management into HIV care systems is vital.
Recent findings: Since May 2022, Mpox caused by Orthopoxvirus monkeypox (MPV) Clade IIb, has affected 126 countries. In 2024, Clade Ib emerged in the Democratic Republic of Congo, leading to its declaration as a Public Health Emergency of International Concern (PHEIC). Research on MPV-HIV co-infections has provided genomic insights and protective strategies for PWH. Antivirals like tecovirimat show promise despite emerging resistance concerns.
Summary : The global Mpox outbreak caused by Clade IIb and the emergence of Clade Ib underscores its growing threat. Mpox disproportionately impacts PWH, leading to severe outcomes and higher fatality rates. This review emphasizes clinical challenges, genomic advances, and prevention strategies. Enhanced surveillance, vaccination, and tailored therapies are essential to addressing this evolving health crisis. | en_US |
| Affilliation | Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brasil. / Estado de Minas Gerais Fundação Ezequiel Dias. Laboratório Central de Saúde Pública. Belo Horizonte, MG, Brasil. | en_US |
| Affilliation | Universidade Federal de Minas Gerais. Departamento de Microbiologia. Belo Horizonte, MG, Brasil. | en_US |
| Affilliation | Fundação Oswaldo Cruz. Instituto Rene Rachou. Belo Horizonte, MG, Brasil. | en_US |
| Subject | HIV | en_US |
| Subject | Mpox | en_US |
| Subject | Immunomodulation | en_US |
| Embargo date | 3100-12-31 | |
